12-24 Hours
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Zomitan 2.5
Incepta Pharmaceuticals Ltd.
Generic: Zolmitriptan
Safety Advices
বাংলা
English
UNSAFE
Zomitan 2.5 may cause excessive drowsiness with alcohol.
CONSULT YOUR DOCTOR
Zomitan 2.5 may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
SAFE IF PRESCRIBED
Zomitan 2.5 is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
SAFE
Zomitan 2.5 does not usually affect your ability to drive.
CAUTION
Zomitan 2.5 should be used with caution in patients with severe kidney disease. Dose adjustment of Zomitan 2.5 may be needed. Please consult your doctor.
CAUTION
Zomitan 2.5 should be used with caution in patients with liver disease. Dose adjustment of Zomitan 2.5 may be needed. Please consult your doctor.
Medicine Overview of Zomitan 2.5 2.5mg Tablet
Introduction
Zomitan 2.5 is used to treat acute migraine attacks. It works by narrowing the blood vessels, thereby relieving migraine headaches and preventing the attack from becoming worse. Zomitan 2.5 may be taken with or without food. Never skip any doses and try to finish the full course of treatment even if you feel better. In case you missed a dose, take it as soon as you remember it. You should continue to take this medicine as long as the doctor advises and do not stop taking it suddenly. Side effects associated with the use of this medicine include dizziness, dryness...
... Show moreUses of Zomitan 2.5
- Acute migraine headache
Side effects of Zomitan 2.5
Common
- Dizziness
- Dryness in mouth
- Nausea
- Heaviness
- Flushing (sense of warmth in the face, ears, neck and trunk)
- Tightness sensation
- Feeling of cold
- Drowsiness
- Fatigue
- Peripheral neuropathy (tingling and numbness of feet and hand)
How to use Zomitan 2.5
Take this medicine in the dose and duration as advised by your doctor. Do not handle the strips/film with wet hands. Keep it in your mouth but do not swallow it. Zomitan 2.5 may be taken with or without food, but it is better to take it at a fixed time.
How Zomitan 2.5 works
Migraine headaches occur due to the dilatation (swelling) of blood vessels in the head. Zomitan 2.5 works by narrowing these blood vessels, thus relieving the migraine headache.
Quick Tips
- You have been prescribed Zolitas ODS 5 Strip for treatment of migraine headaches.
- Some tips that may help avoid a migraine attack:
- It may cause sleepiness. Don't drive or do anything that requires mental focus until you know how it affects you.
- Notify your doctor if your migraine occurs more often after starting the medication.
- Notify your doctor if you have stomach pain, headache, bloody diarrhoea or worsening high blood pressure.
- Inform your doctor if you have a history of heart disease or stroke.
- This medication does not prevent migraine attacks from happening.
Brief Description
Indication
Acute migraine attacks
Administration
May be taken with or without food.
Adult Dose
Oral
Acute migraine attacks
Adult: Initially, 2.5 mg. A 2nd dose may be taken at least 2 hr after the 1st dose if symptoms recur within 24 hr. Max dose: 10 mg in 24 hr. Safety of treating > three headaches in a 30-day period has not been established.
Hepatic impairment: Dose reduction may be needed with BP monitoring. Moderate to severe: Max dose: 5 mg/24 hr
Renal Dose
After orally dosing zolmitriptan, renal clearance was Reduced by 25% in patients with severe renal impairment (Clcr ?5 ?25mL/min) compared to the normal group (Clcr ?70 mL/min);
No significant change in renal clearance was observed in the moderately renally impaired group (Clcr ?26 ?50 mL/min).
Contraindication
Patients at risk of coronary artery disease (post-menopausal women, men >40 yr, hypertension, hypercholesterolemia, smoking, obesity, DM, family history of coronary artery disease) unless evaluated. Wolff-Parkinson-White syndrome; arrhythmias associated with accessory cardiac conduction pathways; previous cerebrovascular accident; uncontrolled or severe hypertension; ischaemic heart disease, history of MI, coronary vasospasm, transient ischaemic attack. Basilar or hemiplegic migraine.
Mode of Action
Zolmitriptan is a selective agonist for serotonin (5HT1 receptors). It relieves migraine by selective constriction of intracranial blood vessels, neuropeptide release inhibition and decreased transmission in the trigeminal pain pathway.
Precaution
Use only if there is a clear diagnosis of migraine; exclude other potentially serious neurological conditions. Monitor BP closely. May impair ability to drive or operate machinery. Pregnancy and lactation. Child. Moderate to severe hepatic impairment. Prior CV evaluation for patients with risk factors of coronary heart disease; admin of first dose under close supervision and ECG if satisfactory CV assessment in these patients. Periodic CV evaluation for patients with risk factors of coronary arteries on zolmitriptan. Avoid oral disintegrating formulation for patients with phenylketouria. Long term use may cause accumulation of zolmitriptan in melanin rich tissue (e.g. eye). Lactation:...
... Show moreSide Effect
1-10%
Dizziness (6-10%),Neck/throat/jaw pain (4-10%),Parasthesia (5-9%),Nausea (4-9%),Weakness (3-9%),Somnolence (5-8%),Warm/cold sensation (5-7%),Xerostomia (3-5%),Chest pain (2-4%),Diaphoresis (3%),Pain (2-3%),Dyspepsia (1-3%),Dysphagia (2%),Myasthenia (2%),Palpation (2%),Vertigo (2%),Hypoesthesia (1-2%),Myalgia (1-2%)
<1%
QT prolongation,Bradycardia,Tachycardia,Thrombophlebitis,Postural hypotension,Hyperglycemia,Alk phos increased,Arthritis,Twitching,Myocardial infarction and artery vasospasm in patients with CAD risk factors
Potentially Fatal: Cardiac arrhythmias, MI, subarachnoid haemorrhage.
Interaction
Increased risk of serotonin syndrome with SSRI, selective serotonin- and norepinephrine-reuptake inhibitors (SNRI). Increased zolmitriptan concentrations with cimetidine, quinolone antibacterials and drugs that inhibit the cytochrome P450 isoenzyme CYP1A2. Potentially Fatal: Increased risk of fatal serotonin syndrome with sibutramine. Increased risk of serotonin syndrome with MAOI and reversible inhibitors of monoamine oxidase type-A (RIMA); do not use zolmitriptan during and for 2 wk after the use of MAOI and RIMAs Do not use within 24 hr of treatment with another 5-HT1 agonist. Increased risk of additive vasoconstriction with ergot alkaloids; zolmitriptan should not be taken within 24 hr of any...
... Show moreব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
